Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497514 | 1.00 | MTNR1A (0.41) | MTNR1AMTNR1BMAPTDGAT1PTGER4 | |
| SCHEMBL30940042 | 0.88 | KLKB1 (0.39) | MTNR1AMTNR1BMAPTDGAT1NPC1 | |
| SCHEMBL30850120 | 0.88 | MTNR1A (0.40) | MTNR1AMTNR1BMAPTDGAT1NPC1 | |
| SCHEMBL23514578 | 0.80 | DGAT1 (0.38) | MTNR1AMTNR1BMAPTDGAT1NPC1 | |
| SCHEMBL20552043 | 0.79 | DGAT1 (0.35) | MTNR1AMTNR1BMAPTDGAT1NPC1 | |
| SCHEMBL31497518 | 0.79 | DGAT1 (0.39) | MTNR1AMTNR1BMAPTDGAT1NPC1 | |
| SCHEMBL31497510 | 0.79 | MAPT (0.39) | MTNR1AMTNR1BMAPTDGAT1PTGER4 | |
| SCHEMBL24096645 | 0.79 | MTNR1A (0.45) | MTNR1AMTNR1BMAPTDGAT1PTGER4 | |
| SCHEMBL19464188 | 0.77 | KDM4E (0.55) | MTNR1AMTNR1BDGAT1NPC1PTPN1 | |
| SCHEMBL29653734 | 0.77 | KDM4E (0.55) | MTNR1AMTNR1BDGAT1NPC1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| EP-4408845-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | MTNR1A 737/4885MTNR1B 836/4885MAPT 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.